S&P 500   3,894.38 (+2.18%)
DOW   31,611.33 (+2.19%)
QQQ   320.26 (+1.95%)
AAPL   124.89 (+2.99%)
MSFT   235.96 (+1.54%)
FB   260.96 (+1.30%)
GOOGL   2,047.00 (+1.24%)
TSLA   707.15 (+4.69%)
AMZN   3,105.70 (+0.41%)
NVDA   544.52 (-0.74%)
BABA   239.77 (+0.85%)
CGC   34.60 (+5.65%)
GE   13.21 (+5.34%)
MU   93.91 (+2.60%)
NIO   49.20 (+7.47%)
AMD   85.03 (+0.62%)
T   28.38 (+1.76%)
F   11.94 (+2.05%)
ACB   11.21 (+6.56%)
DIS   195.88 (+3.62%)
BA   225.66 (+6.44%)
NFLX   548.24 (+1.74%)
BAC   35.66 (+2.74%)
S&P 500   3,894.38 (+2.18%)
DOW   31,611.33 (+2.19%)
QQQ   320.26 (+1.95%)
AAPL   124.89 (+2.99%)
MSFT   235.96 (+1.54%)
FB   260.96 (+1.30%)
GOOGL   2,047.00 (+1.24%)
TSLA   707.15 (+4.69%)
AMZN   3,105.70 (+0.41%)
NVDA   544.52 (-0.74%)
BABA   239.77 (+0.85%)
CGC   34.60 (+5.65%)
GE   13.21 (+5.34%)
MU   93.91 (+2.60%)
NIO   49.20 (+7.47%)
AMD   85.03 (+0.62%)
T   28.38 (+1.76%)
F   11.94 (+2.05%)
ACB   11.21 (+6.56%)
DIS   195.88 (+3.62%)
BA   225.66 (+6.44%)
NFLX   548.24 (+1.74%)
BAC   35.66 (+2.74%)
S&P 500   3,894.38 (+2.18%)
DOW   31,611.33 (+2.19%)
QQQ   320.26 (+1.95%)
AAPL   124.89 (+2.99%)
MSFT   235.96 (+1.54%)
FB   260.96 (+1.30%)
GOOGL   2,047.00 (+1.24%)
TSLA   707.15 (+4.69%)
AMZN   3,105.70 (+0.41%)
NVDA   544.52 (-0.74%)
BABA   239.77 (+0.85%)
CGC   34.60 (+5.65%)
GE   13.21 (+5.34%)
MU   93.91 (+2.60%)
NIO   49.20 (+7.47%)
AMD   85.03 (+0.62%)
T   28.38 (+1.76%)
F   11.94 (+2.05%)
ACB   11.21 (+6.56%)
DIS   195.88 (+3.62%)
BA   225.66 (+6.44%)
NFLX   548.24 (+1.74%)
BAC   35.66 (+2.74%)
S&P 500   3,894.38 (+2.18%)
DOW   31,611.33 (+2.19%)
QQQ   320.26 (+1.95%)
AAPL   124.89 (+2.99%)
MSFT   235.96 (+1.54%)
FB   260.96 (+1.30%)
GOOGL   2,047.00 (+1.24%)
TSLA   707.15 (+4.69%)
AMZN   3,105.70 (+0.41%)
NVDA   544.52 (-0.74%)
BABA   239.77 (+0.85%)
CGC   34.60 (+5.65%)
GE   13.21 (+5.34%)
MU   93.91 (+2.60%)
NIO   49.20 (+7.47%)
AMD   85.03 (+0.62%)
T   28.38 (+1.76%)
F   11.94 (+2.05%)
ACB   11.21 (+6.56%)
DIS   195.88 (+3.62%)
BA   225.66 (+6.44%)
NFLX   548.24 (+1.74%)
BAC   35.66 (+2.74%)
Log in
NASDAQ:EXAS

Exact Sciences Stock Forecast, Price & News

$137.75
+1.63 (+1.20 %)
(As of 03/1/2021 10:22 AM ET)
Add
Compare
Today's Range
$135.91
Now: $137.75
$140.31
50-Day Range
$131.10
MA: $144.45
$155.01
52-Week Range
$35.25
Now: $137.75
$159.54
Volume12,829 shs
Average Volume1.87 million shs
Market Capitalization$23.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.64
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Exact Sciences logo

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXAS
CUSIP30063P10
Phone608-535-8815
Employees4,800
Year Founded1995

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$876.29 million
Book Value$17.62 per share

Profitability

Net Income$-83,990,000.00

Miscellaneous

Market Cap$23.29 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.56 out of 5 stars

Medical Sector

381st out of 1,962 stocks

Commercial Physical Research Industry

7th out of 42 stocks

Analyst Opinion: 2.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$137.75
+1.63 (+1.20 %)
(As of 03/1/2021 10:22 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Exact Sciences (NASDAQ:EXAS) Frequently Asked Questions

Is Exact Sciences a buy right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Exact Sciences stock.
View analyst ratings for Exact Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Exact Sciences?

Wall Street analysts have given Exact Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Exact Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Exact Sciences' next earnings date?

Exact Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Exact Sciences
.

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings data on Monday, February, 15th. The medical research company reported ($2.79) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $2.60. Exact Sciences had a negative trailing twelve-month return on equity of 11.71% and a negative net margin of 25.27%.
View Exact Sciences' earnings history
.

How has Exact Sciences' stock been impacted by Coronavirus?

Exact Sciences' stock was trading at $57.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EXAS shares have increased by 137.4% and is now trading at $137.25.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for EXAS?

15 Wall Street analysts have issued 12 month target prices for Exact Sciences' shares. Their forecasts range from $70.00 to $226.00. On average, they expect Exact Sciences' stock price to reach $145.31 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price.
View analysts' price targets for Exact Sciences
or view top-rated stocks among Wall Street analysts.

Who are Exact Sciences' key executives?

Exact Sciences' management team includes the following people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 55, Pay $1.82M)
  • Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 43, Pay $701.77k)
  • Ms. Ana Hooker, Sr. VP of Operations (Age 55, Pay $627.49k)
  • Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 56, Pay $741.87k)
  • Mr. Mark Stenhouse, Advisor (Age 53, Pay $1.22M)
  • Mr. Jake Orville, Sr. VP of Pipeline (Age 47, Pay $769.63k)
  • Mr. G. Bradley Cole, Gen. Mang. of Precision Oncology (Age 65, Pay $1.23M)
  • Mr. Gary Frings, Chief Information Officer
  • Dr. Scott C. Johnson Ph.D., Chief Science Officer and Sr. VP of R&D
  • Ms. Megan Jones, Associate Mang. of Investor Relations

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

141 employees have rated Exact Sciences CEO Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among Exact Sciences' employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Exact Sciences' key competitors?

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), The Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (2.12%), Sumitomo Mitsui Trust Holdings Inc. (1.22%), Zevenbergen Capital Investments LLC (1.21%), Nikko Asset Management Americas Inc. (0.88%), Frontier Capital Management Co. LLC (0.77%) and Baillie Gifford & Co. (0.76%). Company insiders that own Exact Sciences stock include G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Sarah Condella, Scott C Johnson and Torsten Hoof.
View institutional ownership trends for Exact Sciences
.

Which major investors are selling Exact Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Primecap Management Co. CA, Zevenbergen Capital Investments LLC, Frontier Capital Management Co. LLC, Factory Mutual Insurance Co., Nuveen Asset Management LLC, C WorldWide Group Holding A S, and Handelsbanken Fonder AB. Company insiders that have sold Exact Sciences company stock in the last year include Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Sarah Condella, and Torsten Hoof.
View insider buying and selling activity for Exact Sciences
or view top insider-selling stocks.

Which major investors are buying Exact Sciences stock?

EXAS stock was purchased by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Renaissance Technologies LLC, Avidity Partners Management LP, Artisan Partners Limited Partnership, Columbus Circle Investors, Victory Capital Management Inc., and Baillie Gifford & Co..
View insider buying and selling activity for Exact Sciences
or or view top insider-buying stocks.

How do I buy shares of Exact Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $137.25.

How much money does Exact Sciences make?

Exact Sciences has a market capitalization of $23.21 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How many employees does Exact Sciences have?

Exact Sciences employs 4,800 workers across the globe.

When was Exact Sciences founded?

Exact Sciences was founded in 1995.

What is Exact Sciences' official website?

The official website for Exact Sciences is www.exactsciences.com.

Where are Exact Sciences' headquarters?

Exact Sciences is headquartered at 5505 ENDEAVOR LANE, MADISON WI, 53719.

How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.